文献速递骨软组织肉瘤与黑色素瘤

DTS-201多柔比星前药1小时静脉输注每3周一次的首次人体I期研究

First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
PubMed 文献 · Eur J Cancer · 2017-10-19

这是一项首次人体I期研究,评估多柔比星前药DTS-201在晚期或转移性实体瘤患者中的安全性、药代动力学和推荐II期剂量。25例患者接受80-400 mg/m2四个剂量水平的1小时静脉输注,每3周一次。DL4(400 mg/m2)为最大耐受剂量和推荐II期剂量,主要毒性为骨髓抑制,未观察到治疗相关严重心脏不良事件。

要点

  • DTS-201推荐II期剂量为400 mg/m2,每3周一次1小时静脉输注。
  • DL4(400 mg/m2)为最大耐受剂量,DL3和DL4观察到剂量限制性毒性。
  • 主要毒性为骨髓抑制,推荐剂量下NCI-CTC III-IV级中性粒细胞减少常见。

核心结论

  • DTS-201在经重度预处理的实体瘤患者中耐受良好且安全。
  • 可给予高等效剂量多柔比星而无严重药物相关心脏事件。
  • DTS-201显示出临床活性证据,一例软组织肉瘤患者达到确认的部分缓解。
  • 推荐II期剂量为400 mg/m2。

研究设计与样本

  • 首次人体I期研究,纳入25例晚期或转移性实体瘤患者,中位年龄58岁(范围30-72岁)。
  • DTS-201以1小时静脉输注给药,每3周一次。
  • 剂量递增采用改良Fibonacci方案,共四个剂量水平(80-400 mg/m2,相当于常规多柔比星45-225 mg/m2)。
  • 中位治疗周期数为2(范围1-8)。

主要发现

  • 前两个剂量水平未发生剂量限制性毒性。
  • DL3和DL4观察到3例剂量限制性毒性:DL3为腹泻,DL4为呕吐和中性粒细胞减少。
  • DL4(400 mg/m2)被认为是最大耐受剂量。
  • 骨髓抑制为主要毒性,推荐剂量下NCI-CTC III-IV级中性粒细胞减少常见。
  • 非血液学不良反应为轻至中度,包括恶心、厌食、乏力和脱发。

关键数值与推荐

  • 推荐II期剂量为400 mg/m2,每3周一次1小时静脉输注。
  • DL4(400 mg/m2)为最大耐受剂量。
  • DL3和DL4观察到剂量限制性毒性,前两个剂量水平未发生。

临床怎么用

  • DTS-201推荐II期剂量为400 mg/m2,每3周一次1小时静脉输注。
  • 治疗中需关注骨髓抑制,尤其是中性粒细胞减少。
  • 非血液学不良反应包括恶心、厌食、乏力和脱发,多为轻至中度。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: DTS-201 is a doxorubicin (Dox) prodrug that shows encouraging data in experimental models in terms of both efficacy and safety compared with conventional Dox. The purpose of this phase I study was to assess the safety profile, to establish the recommended dose (RD) for clinical phase II studies and to assess potential anticancer activity of the compound. EXPERIMENTAL DESIGN: DTS-201 was administered as a 1-hour infusion every 3 weeks in eligible patients with advanced solid tumours according to common clinical phase I criteria. Dose escalation was performed according to a modified Fibonacci schema. RESULTS: Twenty-five patients with a median age of 58 years (range, 30-72) were enrolled in the study. The median number of treatment cycles was 2 (range, 1-8). DTS-201 was administered at four dose levels (DLs) ranging from 80 to 400 mg/m2, which is equivalent to 45-225 mg/m2 of conventional Dox. No dose-limiting toxicity (DLT) occurred at the first two DLs. Three DLTs were observed at DL3 and DL4 (diarrhoea for DL3, vomiting and neutropenia for DL4). DL4 (400 mg/m2) was considered the maximum tolerated dose. Myelosuppression was the main toxicity, and NCI-CTC grade III-IV neutropenia was common at RD. Non-haematological adverse reactions were mild to moderate and included nausea, anorexia, asthenia and alopecia. No treatment-related severe cardiac adverse events were observed. CONCLUSIONS: DTS-201 is well tolerated and safe in heavily pretreated solid tumour patients. A high equivalent dose of Dox could be delivered without severe drug-related cardiac events. DTS-201 showed evidence of clinical activity with a confirmed partial response in a patient with soft-tissue sarcoma. The recommended phase II dose is 400 mg/m2.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schöffski P, Delord JP, Brain E, et al. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours. Eur J Cancer. 2017. PMID: 29055839. doi:10.1016/j.ejca.2017.09.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。